百济神州(ONC)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ONC 百济神州

交易中 12-16 09:36:10 EST

301.64

-9.03

-2.91%

最高302.55	最低299.50	成交量5.48万
今开301.08	昨收310.67	日振幅0.98%
总市值358.95亿	流通市值228.17亿	总股本1.19亿
成交额1,651万	换手率0.07%	流通股本7,564万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"百济神州","latestPrice":301.64,"timestamp":1765895770453,"preClose":310.67,"halted":0,"volume":54826,"delay":0,"floatShares":75641900,"shares":119000000,"eps":0.584711,"marketStatus":"交易中","change":-9.03,"latestTime":"12-16 09:36:10 EST","open":301.08,"high":302.55,"low":299.5,"amount":16510121.810720002,"amplitude":0.009817,"askPrice":302.14,"askSize":40,"bidPrice":301.63,"bidSize":123,"shortable":3,"etf":0,"ttmEps":0.584711,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1765918800000},"marketStatusCode":2,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":310.67,"preHourTrading":{"tag":"盘前","latestPrice":304.66,"preClose":310.67,"latestTime":"09:20 EST","volume":18427,"amount":5721681.90018,"timestamp":1765894848296},"postHourTrading":{"tag":"盘后","latestPrice":310.67,"preClose":310.67,"latestTime":"18:14 EST","volume":1343,"amount":417227.28,"timestamp":1765840467073},"volumeRatio":9.700429,"impliedVol":0.4193,"impliedVolPercentile":0.2833},"requestUrl":"/m/hq/s/ONC/tweets","defaultTab":"tweets","newsList":[{"id":"2591697904","title":"午后突发！港股通创新药ETF（520880）跌2.77%创阶段新低，康方生物、百济神州等大权重龙头领跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2591697904","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591697904?lang=zh_cn&edition=full","pubTime":"2025-12-15 13:39","pubTimestamp":1765777140,"startTime":"0","endTime":"0","summary":"12月15日午后，港股通创新药板块加速下跌，港股通创新药ETF一度跌至2.77%创近5个月新低，龙头股齐挫，康方生物跌超5%，百济神州跌逾6%，中国生物制药、信达生物跌超3%。　　阶段新低之际，“抄底”资金或再行动，港股通创新药ETF场内宽幅溢价，显示买盘资金相对强势。　　把握港股创新药低吸窗口期，认准同类最大港股通创新药ETF及其场外联接基金，标的指数恒生港股通创新药精选指数具备三大独特优势：","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2025-12-15/doc-inhawauf3976382.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0417516571.SGD","LU0307460666.USD","LU0417516902.SGD","06160","LU2476274720.SGD","LU0348767384.USD","BK0239","BK1583","LU2778985437.USD","LU0561508036.HKD","LU0417516738.SGD","BK1574","LU0348827113.USD","IE00BPRC5H50.USD","BK4526","LU0540923850.HKD","LU0348784397.USD","LU0588546209.SGD","LU1719994722.HKD","BK1588","LU2476274308.USD","ONC","LU1303224171.USD","LU1961090484.USD","IE00B5MMRT66.SGD","LU1720050803.USD","BK1161","LU0348825331.USD","LU1794554557.SGD","LU2488822045.USD","BK1500","688235","BK4585","BK4139","LU0348735423.USD","LU0348783233.USD","LU2328871848.SGD","LU1251922891.USD","IE00B543WZ88.USD","LU1969619763.USD","LU2399975544.HKD","LU1770034418.SGD","LU0634319403.HKD","520880","09926","LU0348766576.USD"],"gpt_icon":0},{"id":"2590348233","title":"中信证券：医保谈判成功率创近年新高，关注创新药企","url":"https://stock-news.laohu8.com/highlight/detail?id=2590348233","media":"瑞财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590348233?lang=zh_cn&edition=full","pubTime":"2025-12-09 14:57","pubTimestamp":1765263437,"startTime":"0","endTime":"0","summary":"瑞财经 严明会近日，中信证券指出，2025年12月7日，2025创新药高质量发展大会在广州举行，国家医保局现场发布了2025年《国家基本医疗保险、生育保险和工伤保险药品目录》及《商业健康保险创新药品目录》。在基本医保目录上，最终114个成功纳入，其中包含50个1类创新药，成功率为88%，谈判成功率创近7年新高。与此同时，首版商保目录发布，共纳入19款产品，包含5款CAR-T产品。中信证券认为，伴随着国家对创新药持续的政策倾斜和鼓励支持，医保和商保的双轨并行，有望带动支付多元化，创新药企的回报有望逐步提升。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512091457209532ed86&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512091457209532ed86&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","ONC","02359","BK4139","06160","BK4526"],"gpt_icon":0},{"id":"2590348255","title":"药价登记，出海新支点","url":"https://stock-news.laohu8.com/highlight/detail?id=2590348255","media":"药视声Medispace","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590348255?lang=zh_cn&edition=full","pubTime":"2025-12-09 11:58","pubTimestamp":1765252739,"startTime":"0","endTime":"0","summary":"本土龙头企业如恒瑞医药、百济神州等持续投入高额研发费用，其中恒瑞医药已在中国获批上市23款1类新分子实体创新药，覆盖肿瘤、自身免疫等领域。从早期的原料药出口，到现在的创新药License-out，2025年上半年国产创新药对外授权交易总金额已接近660亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209164810a43d48ce&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209164810a43d48ce&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4585","06160","ONC","01276","BK4526"],"gpt_icon":0},{"id":"2589877119","title":"19种药品纳入首版商保目录，5款CAR-T疗法集体入围，影响有多大？","url":"https://stock-news.laohu8.com/highlight/detail?id=2589877119","media":"澎湃新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589877119?lang=zh_cn&edition=full","pubTime":"2025-12-07 21:37","pubTimestamp":1765114670,"startTime":"0","endTime":"0","summary":"在7日的大会现场，国家医保局相关负责人还为入选商保创新药目录的企业代表颁发了证书。根据此前公布的数据，首版商保创新药目录申报信息共有141份，涉及药品通用名141个，121个通过形式审查，实际参与商保创新药目录价格协商的药品24个。进入商保目录后，公司CAR-T疗法的对外价格还是不变的，但对于保险公司会有一个折扣价格。两款药物均出现在首版目录名单，有望造福更多AD患者。从最终的结果来看，该产品未能进入商保目录。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251207213959a439684c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251207213959a439684c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196","06160","LU0154236417.USD","BK4585","02171","01228","BK4022","02161","BK4532","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","BK4230","LU1093756168.USD","NVO","BK4007","BK4588","BK4599","688235","LU1093756325.SGD","ONC"],"gpt_icon":0},{"id":"2589387525","title":"百济神州两款药品进入2025年商保创新药目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589387525","media":"北京商报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589387525?lang=zh_cn&edition=full","pubTime":"2025-12-07 13:56","pubTimestamp":1765086982,"startTime":"0","endTime":"0","summary":"【百济神州两款药品进入2025年商保创新药目录】12月7日，《商业健康保险创新药品目录（2025年）》正式发布，18家创新药企业的19款药品成功纳入，其中，百济神州有两款药品成功纳入，包括达妥昔单抗β注射液以及注射用泽尼达妥单抗。百济神州也是唯一一家两款产品进入商保创新药目录的创新药企。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512073584561139.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512073584561139.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1303224171.USD","BK4585","159992","ONC","06978","BK1500","BK1583","BK1588","06160","BK4139","LU1969619763.USD","BK1574","BK0239","BK1161","LU0307460666.USD","BK4526","LU1770034418.SGD","LU1251922891.USD","LU2328871848.SGD","688235","LU0588546209.SGD","LU1719994722.HKD"],"gpt_icon":0},{"id":"2588002521","title":"百济神州(06160)授出合共2.13万个受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2588002521","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588002521?lang=zh_cn&edition=full","pubTime":"2025-12-04 16:53","pubTimestamp":1764838411,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布公告，于2025年11月28日，董事会薪酬委员会根据2016期权及激励计划的条款授予147名承授人合共2.13万股美国存托股份受限制股份单位。该等受限制股份单位相当于27.66万股股份，约占本公告之日公司发行股份总数的0.02%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377693.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1303224171.USD","BK4585","ONC","BK1500","BK1583","BK1588","06160","BK4139","LU1969619763.USD","BK0239","BK1161","LU0307460666.USD","BK4526","LU1770034418.SGD","LU1251922891.USD","LU2328871848.SGD","688235","LU0588546209.SGD","LU1719994722.HKD"],"gpt_icon":0},{"id":"2585015452","title":"近一个月内，我武生物等多家国内药企研发项目终止！","url":"https://stock-news.laohu8.com/highlight/detail?id=2585015452","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585015452?lang=zh_cn&edition=full","pubTime":"2025-11-24 15:42","pubTimestamp":1763970164,"startTime":"0","endTime":"0","summary":"如近一个月内，多家国内药企的研发项目就已终止。11月14日消息，我武生物公告称，公司管理层决定终止烟曲霉点刺液研发项目，不再开展后续临床试验。该药物用于辅助诊断因烟曲霉致敏引起的I型变态反应性疾病。11月12日，同润生物宣布启动清算解散。11月3日，派格生物发布公告称，已于10月28日申请自愿解散非全资附属公司上海迈迹。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511241545319517006f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511241545319517006f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ONC","06160","BK4585","BK4526"],"gpt_icon":0},{"id":"2585090452","title":"科创生物医药ETF涨1.42%，成交额737.09万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2585090452","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585090452?lang=zh_cn&edition=full","pubTime":"2025-11-24 15:05","pubTimestamp":1763967900,"startTime":"0","endTime":"0","summary":"11月24日，鹏华上证科创板生物医药ETF收盘涨1.42%，成交额737.09万元。该基金成立于2025年3月12日，全称为鹏华上证科创板生物医药交易型开放式指数证券投资基金，管理费率每年0.50%，托管费率每年0.10%，业绩比较基准为上证科创板生物医药指数收益率。规模上，截至11月21日，其最新份额为2.02亿份，规模2.28亿元；流动性方面，截至11月24日，近20个交易日累计成交金额3.08亿元，日均成交金额1542.47万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511241513169516f1d7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511241513169516f1d7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","BK4526","BK4585","BK4139","ONC"],"gpt_icon":0},{"id":"2585345202","title":"趋势研判！2025年中国BTK抑制剂行业发展历程、产业链、市场规模、竞争格局及发展趋势分析：市场呈现出巨大增长潜力，未来市场竞争愈加激烈[图]","url":"https://stock-news.laohu8.com/highlight/detail?id=2585345202","media":"智研咨询","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585345202?lang=zh_cn&edition=full","pubTime":"2025-11-24 09:12","pubTimestamp":1763946720,"startTime":"0","endTime":"0","summary":"预计2025年全球BTK抑制剂市场规模将达到130亿美元，中国BTK抑制剂市场规模增长至49亿元。目前，我国已批准5种BTK抑制剂用于临床治疗，它们分别为伊布替尼、泽布替尼、阿卡替尼、奥布替尼、匹妥布替尼。随着对BTK抑制剂在疾病发生发展中作用的深入理解和技术的不断进步，我国BTK抑制剂行业正处于快速发展和变革的时期，市场呈现出巨大增长潜力。国内多家药企正在积极研发新一代BTK抑制剂，未来市场竞争将更加激烈。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025112409155095166537&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025112409155095166537&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BCR","BK4585","06160","BK4526","BK4139"],"gpt_icon":0},{"id":"2584095566","title":"港股异动 | 百济神州(06160)高开逾3% 百赫安联合百泽安与化疗的3期临床研究取得积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2584095566","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584095566?lang=zh_cn&edition=full","pubTime":"2025-11-18 09:25","pubTimestamp":1763429130,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百济神州高开逾3%，截至发稿，涨3.53%，报223.2港元，成交额1196.27万港元。消息面上，11月17日，百济神州宣布III期HERIZON-GEA-01研究取得积极结果。中信建投此前指出，百济神州泽布替尼持续放量，上调全年业绩指引。考虑到公司BTK海外放量超预期，以及PD-1在欧盟、日本等其他国家上市放量，以及BCL-2、BTK CDAC、CDK4等重磅管线持续兑现带来商业化进一步兑现，维持“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"4fc0c44f8d8eb43e289164e52c59bade","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1370326.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1303224171.USD","BK1588","BK4139","LU0307460666.USD","688235","LU0588546209.SGD","06160","LU1251922891.USD","BK4526","BK1583","LU2328871848.SGD","BK1500","BK4585","BK0239","LU1719994722.HKD","LU1969619763.USD","ONC","BK1161","LU1770034418.SGD"],"gpt_icon":0},{"id":"2583661900","title":"百济神州授出1.65万股受限制股份单位激励员工","url":"https://stock-news.laohu8.com/highlight/detail?id=2583661900","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583661900?lang=zh_cn&edition=full","pubTime":"2025-11-16 18:28","pubTimestamp":1763288885,"startTime":"0","endTime":"0","summary":"11月16日，百济神州（688235/06160/BGNE）发布公告，2025年11月10日，公司董事会薪酬委员会根据2016期权及激励计划的条款，向143名承授人授出涉及共1.65万股美国存托股份的受限制股份单位。这些受限制股份单位相当于21万股股份，约占公司公告之日发行股份总数的0.01%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511163565527346.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","LU1719994722.HKD","LU1969619763.USD","BK1588","LU1770034418.SGD","ONC","06160","LU1251922891.USD","LU2328871848.SGD","BK4526","BK4139","BK1500","LU1303224171.USD","BK1161","BK4585","LU0588546209.SGD","LU0307460666.USD"],"gpt_icon":0},{"id":"2583041715","title":"百济神州(06160)：授出合共1.65万股美国存托股份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2583041715","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583041715?lang=zh_cn&edition=full","pubTime":"2025-11-14 22:19","pubTimestamp":1763129941,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布公告，于2025年11月10日，董事会薪酬委员会根据2016期权及激励计划的条款授予143名承授人合共1.65万股美国存托股份受限制股份单位。该等受限制股份单位相当于21.4万股股份，约占本公告之日公司发行股份总数的0.01%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369617.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK0239","LU1303224171.USD","688235","LU1969619763.USD","BK4526","BK4139","BK1583","LU1251922891.USD","BK1161","ONC","LU1719994722.HKD","LU0588546209.SGD","BK1500","06160","LU2328871848.SGD","BK1588","LU0307460666.USD","LU1770034418.SGD"],"gpt_icon":0},{"id":"2583351341","title":"11月以来机构调研聚焦成长与防御方向","url":"https://stock-news.laohu8.com/highlight/detail?id=2583351341","media":"大众证券报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583351341?lang=zh_cn&edition=full","pubTime":"2025-11-13 21:51","pubTimestamp":1763041860,"startTime":"0","endTime":"0","summary":"Wind数据显示，11月以来，电子、机械设备、电力设备、医药生物、计算机等行业成为机构投资者调研的核心方向。立讯精密、百济神州关注度较高在11月以来的机构调研中，立讯精密、百济神州、汇川技术等企业成为机构“团宠”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251113215346976742f6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251113215346976742f6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4139","BK4585","BK4526","06160"],"gpt_icon":0},{"id":"2583593827","title":"信达生物高管钱镭：百济神州是窗口期的产物","url":"https://stock-news.laohu8.com/highlight/detail?id=2583593827","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583593827?lang=zh_cn&edition=full","pubTime":"2025-11-13 21:15","pubTimestamp":1763039759,"startTime":"0","endTime":"0","summary":"中国创新药企初具全球竞争力，它们有哪些成功经验可供后来者借鉴？百济神州与信达生物先后成立于2010年和2011年，两者都已经有创新药上市，是中国制药产业的代表性企业。但两家企业所走的道路完全不同。百济神州起步就是创新药和全球化，信达生物则先在本土稳扎稳打，然后才谋划国际市场。近日，信达生物首席研发官钱镭在一场论坛上表示，百济神州是特定时期发展起来的企业，其成长路径缺乏可复制性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511133563777018.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511133563777018.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2488822045.USD","LU2242644610.SGD","LU0588546209.SGD","06160","LU2097828557.USD","BK1161","BK4585","LU0307460666.USD","LU1969619763.USD","BK1583","LU0502904849.HKD","LU1719994722.HKD","BK1589","BK1588","LU1770034418.SGD","BK1500","HK0000165453.HKD","LU1303224171.USD","LU2097828474.EUR","LU0455707207.USD","LU2097828631.EUR","LU2328871848.SGD","ONC","LU2097828805.USD","01801","LU2097828714.EUR","BK4139","BK4526","LU1251922891.USD"],"gpt_icon":0},{"id":"2583566554","title":"百济神州第三季度归母净利润6.89亿元 同比扭亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2583566554","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583566554?lang=zh_cn&edition=full","pubTime":"2025-11-13 18:33","pubTimestamp":1763030039,"startTime":"0","endTime":"0","summary":"11月12日，百济神州(688235)公布2025年三季报，公司营业收入为276.0亿元，同比上升44.2%；归母净利润自去年同期亏损36.9亿元成功扭亏，实现归母净利润11.4亿元；扣非归母净利润自去年同期亏损39.9亿元成功扭亏，实现扣非归母净利润9.69亿元；经营现金流净额为42.82亿元；EPS(全面摊薄)为0.739元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511133563677135.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ONC","06160"],"gpt_icon":0},{"id":"2583441513","title":"一哥新高，要起风了","url":"https://stock-news.laohu8.com/highlight/detail?id=2583441513","media":"CPHI制药在线","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583441513?lang=zh_cn&edition=full","pubTime":"2025-11-13 18:03","pubTimestamp":1763028209,"startTime":"0","endTime":"0","summary":"关注并星标CPHI制药在线百济神州三季报交上了一份高分的答卷，2025年第三季度，百济神州实现营收14.12亿美元，同比去年第三季度增长41%；2025年前三季度，百济神州实现营收38.45亿美元，同比去年前三季度增长43%。最近一次获批是在2024年3月7日，批准治疗复发或难治性滤泡性细胞瘤。百济神州目前的战略是三位一体，用泽布替尼，Bcl-2抑制剂索托克拉以及BTK为靶点的PROTAC药物，来维持其在CLL适应症乃至整个血液疾病适应症的地位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251113191029a6f6e18c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251113191029a6f6e18c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4526","LU2211817866.USD","BK4534","ONC","LU0511384066.AUD","LU0057025933.USD","LU0175139822.USD","LU2238339852.HKD","LU2089279066.USD","LU2229751404.USD","IE00BFXG0V08.USD","06160","WM","LU2463526074.USD","LU0124676726.USD","LU0289739343.SGD","LU0472753341.HKD","LU0689626769.HKD","LU2041044095.USD","LU2298064838.USD","BK4120","LU0289961442.SGD","BK4139","LU2211814178.USD","LU2355687059.USD","LU1974910355.USD","MTD","LU2023250504.SGD","LU1093756325.SGD","BK4121","LU2413666426.HKD","LU0347712357.USD","LU1430594728.SGD","LU0289960550.SGD","LU1093756168.USD","LU1585245621.USD","LU1623119135.USD","IE00BYQQ9H92.USD","LU1923621640.USD","ORR","LU2362540622.SGD","LU2125910336.SGD","BK4566","LU0069063385.USD","LU2240825500.USD","LU2106854487.HKD","BK4588","LU2125910179.SGD","LU1712237335.SGD","LU1917777945.USD","LU2413666699.HKD"],"gpt_icon":1},{"id":"2583513477","title":"科创生物医药ETF涨1.77%，成交额1756.48万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2583513477","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583513477?lang=zh_cn&edition=full","pubTime":"2025-11-13 15:05","pubTimestamp":1763017500,"startTime":"0","endTime":"0","summary":"11月13日，鹏华上证科创板生物医药ETF（588250）收盘涨1.77%，成交额1756.48万元。该基金成立于2025年3月12日，全称为鹏华上证科创板生物医药交易型开放式指数证券投资基金，管理费率每年0.50%，托管费率每年0.10%，业绩比较基准为上证科创板生物医药指数收益率。规模上，截止11月12日，其最新份额为2.06亿份，规模2.44亿元；流动性方面，截止11月13日，近20个交易日累计成交金额2.90亿元。该基金现任基金经理为林嵩，任职期内收益17.13%。最新定期报告显示，其重仓股包括联影医疗、百济神州等。市场有风险，投资需谨慎。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111315231997668c84&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111315231997668c84&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","BK4526","BK4585","BK4139","ONC"],"gpt_icon":0},{"id":"2583159440","title":"展望2026年：医药行业有望维持超配地位","url":"https://stock-news.laohu8.com/highlight/detail?id=2583159440","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583159440?lang=zh_cn&edition=full","pubTime":"2025-11-13 12:08","pubTimestamp":1763006911,"startTime":"0","endTime":"0","summary":"有机构近日研报指出，2026年医药行业内外因催化因素将持续发力，行业正回归临床价值导向的发展正轨，有望维持超配地位。经过多年研发投入与技术积累，中国医药企业已从仿制药为主的阶段，迈入创新药械密集产出期。在健康中国战略的长期指引下，医药行业的超配价值将不断凸显，成为资本市场中具潜力的投资领域之一。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251113121124a49dfc87&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251113121124a49dfc87&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2097828557.USD","06160","HK0000165453.HKD","BK1161","LU2097828714.EUR","LU2328871848.SGD","LU2488822045.USD","ONC","LU2097828474.EUR","BK1583","BK1589","LU1969619763.USD","LU2242644610.SGD","LU0455707207.USD","LU2097828631.EUR","LU0502904849.HKD","01801","LU2097828805.USD"],"gpt_icon":0},{"id":"1139577547","title":"港股生物医药股逆势走高！百济神州涨超7%，百奥赛图-B涨超6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1139577547","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139577547?lang=zh_cn&edition=full","pubTime":"2025-11-13 09:42","pubTimestamp":1762998120,"startTime":"0","endTime":"0","summary":"11月13日，港股生物医药股逆势走高，$百济神州(06160)$涨超7%，$百奥赛图-B(02315)$涨超6%，$映恩生物-B(09606)$涨超5%，$三生制药(01530)$、$信达生物(01801)$、$来凯医药-B(02105)$涨超3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","ONC","02315","LU2097828805.USD","LU0588546209.SGD","LU0455707207.USD","LU0502904849.HKD","LU2097828631.EUR","LU0307460666.USD","BK1593","LU1969619763.USD","01801","BK4139","LU2097828714.EUR","06160","09939","HK0000252160.HKD","BK4526","BK1588","BK1500","HK0000252152.HKD","LU2097828474.EUR","BK1589","LU2242644610.SGD","BK1161","02105","LU1251922891.USD","LU1303224171.USD","BK1583","LU1770034418.SGD","LU2328871848.SGD","HK0000500386.USD","09606","LU2543165471.USD","LU2097828557.USD","01530","HK0000165453.HKD","BK4585","LU1719994722.HKD"],"gpt_icon":0},{"id":"1170007002","title":"百济神州前三季度同比转亏为盈，泽布替尼美欧市场放量超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1170007002","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170007002?lang=zh_cn&edition=full","pubTime":"2025-11-13 09:34","pubTimestamp":1762997640,"startTime":"0","endTime":"0","summary":"11月13日，$百济神州(06160)$涨超6%！前三季度净利润11.39亿元，同比转亏为盈。百济神州披露2025年第三季度报告，公司前三季度实现营收275.95亿元，同比增长44.2%;归属于上市公司股东的净利润11.39亿元，同比扭亏为盈;扣非净利润9.69亿元，同比扭亏为盈;基本每股收益0.81元。业绩增长主要系由于产品收入增长和费用管理推动了经营效率的提升。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"百济神州前三季度同比转亏为盈，泽布替尼美欧市场放量超预期","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1588","LU2328871848.SGD","BK1500","06160","LU0307460666.USD","BK4526","LU1251922891.USD","BK1161","BK4585","LU1719994722.HKD","LU0588546209.SGD","LU1303224171.USD","BK1583","BK4139","LU1969619763.USD","ONC","LU1770034418.SGD"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.beonemedicines.com","stockEarnings":[{"period":"1week","weight":-0.0485},{"period":"1month","weight":-0.1508},{"period":"3month","weight":-0.0505},{"period":"6month","weight":0.229},{"period":"1year","weight":0.7322},{"period":"ytd","weight":0.6819}],"compareEarnings":[{"period":"1week","weight":-0.0042},{"period":"1month","weight":0.0131},{"period":"3month","weight":0.0314},{"period":"6month","weight":0.1394},{"period":"1year","weight":0.1266},{"period":"ytd","weight":0.1615}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"　　百济神州有限公司的主营业务是研究、开发、生产以及商业化创新型药物。公司的主要产品是百悦泽、百泽安、百汇泽、安加维、倍利妥、凯洛斯、萨温珂、凯泽百、普贝希（安维汀生物类似药）、百拓维（注射用戈舍瑞林微球）、泰菲乐（达拉非尼）、迈吉宁（曲美替尼）、维全特（帕唑帕尼）、飞尼妥（依维莫司）、赞可达（塞瑞替尼）。截至本报告期末，公司及其控股子公司拥有的发明专利包括美国发明专利64个、中国发明专利67个、日本发明专利30个、欧洲发明专利15个及其他国家或地区的发明专利135个。","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":0.079635},{"month":2,"riseRate":0.666667,"avgChangeRate":0.038229},{"month":3,"riseRate":0.4,"avgChangeRate":-0.025903},{"month":4,"riseRate":0.4,"avgChangeRate":0.021288},{"month":5,"riseRate":0.4,"avgChangeRate":-0.019094},{"month":6,"riseRate":0.5,"avgChangeRate":0.012468},{"month":7,"riseRate":0.8,"avgChangeRate":0.147208},{"month":8,"riseRate":0.6,"avgChangeRate":0.034201},{"month":9,"riseRate":0.6,"avgChangeRate":0.069537},{"month":10,"riseRate":0.5,"avgChangeRate":-0.004517},{"month":11,"riseRate":0.6,"avgChangeRate":0.063715},{"month":12,"riseRate":0.3,"avgChangeRate":-0.041649}],"exchange":"NASDAQ","name":"百济神州","nameEN":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百济神州(ONC)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百济神州(ONC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百济神州,ONC,百济神州股票,百济神州股票老虎,百济神州股票老虎国际,百济神州行情,百济神州股票行情,百济神州股价,百济神州股市,百济神州股票价格,百济神州股票交易,百济神州股票购买,百济神州股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百济神州(ONC)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百济神州(ONC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}